Pfizer's Innovative Migraine-Specific Drug Rimegepant ODT Launches Exclusively on Meituan Pharmacy

On March 9, Pfizer's全新一代偏头痛特异性治疗口服靶向药瑞美吉泮口崩片made its online debut on the Meituan Medicine platform. As the world's * and * innovative CGRP (Calcitonin Gene-Related Peptide) receptor antagonist utilizing patented orally disintegrating tablet technology, this groundbreaking drug effectively blocks key pathways involved in migraine attacks. Following its launch on Meituan Medicine’s instant delivery and self-operated platforms, it will significantly improve patient access and convenience, meeting the critical medication needs of patients during acute migraine episodes and bridging the "last mile" to deliver innovative treatments to those in need.

Improving Pharmaceutical Supply through Digitization, Building a "Headache Station" at Patients' Fingertips

Migraine is a common and disabling condition, often presenting as unilateral or bilateral headaches that can occur in various regions such as the top of the head, forehead, back of the head, or even the entire head. The pain ranges from moderate to severe and is typically throbbing, significantly impacting patients' work and daily life. However, many patients have widespread misconceptions. On one hand, a considerable number of patients believe that all medications have side effects and choose to endure the pain. Unbeknownst to them, migraine treatment should be prompt; in the early stages, when only certain brain areas' pain signals are activated, effective treatment drugs can provide timely relief. Otherwise, the pain will intensify. On the other hand, about 50% of migraine patients use non-specific medications, which not only result in inadequate treatment response and symptom recurrence but also pose risks like medication-overuse headaches from long-term painkiller use and contraindications for patients with cardiovascular diseases. Therefore, there is a significant unmet need for both efficacy and safety.

Ms. Chen Ye, Head of the Migraine Business Unit of Pfizer Global Biopharmaceutical Commercial Group, China, stated: "Pfizer has been deeply rooted in China for 35 years, and migraine is one of our key focus areas. We have a series of breakthrough innovative drugs that are accelerating access for Chinese patients. Through this in-depth collaboration with Meituan Medicine, we will actively respond to the requirements outlined in the State Council's '14th Five-Year Plan' to accelerate the digital supply of healthcare resources and networked services. Leveraging our respective strengths in R&D innovation and digital connectivity, we aim to jointly create an easily accessible 'Headache Station' at patients’ fingertips. By integrating online and offline innovative pharmaceuticals and patient service models, we hope to help migraine sufferers effectively combat their condition and return to healthy lives."

With one-stop health management services, build a comprehensive health protection network for patients.

Due to the complex etiology of migraine and the involvement of multiple disciplines in diagnosis, there have long been significant gaps in the standardized diagnosis and treatment of migraine. The consultation rate for migraine in China is only 52.9%. Following the launch of Rimegepant Orodispersible Tablets on Meituan Medicine's instant delivery and self-operated pharmacy platforms, the platform will integrate one-stop health management services such as doctor education, pharmacist support, follow-up consultations, and prescription renewals, offering a new treatment option for a broader population of migraine patients.

Data from Meituan Medicine shows that after the Spring Festival holiday, consultations for migraine patients increased by nearly 70% compared to during the festival. "We aim to provide users with a diverse selection of medicines, promote the accessibility of innovative drugs, and allow more patients to benefit," said a relevant representative from Meituan Medicine. Migraines affect a wide population and are prone to recurrent attacks, causing unbearable pain during acute episodes. Through in-depth cooperation with Pfizer, Meituan Medicine is using digital methods to enhance awareness and accessibility of innovative drugs, addressing potential user pain points. We hope this will serve as a model to build a health protection network for patients across more disease areas, drive innovation in disease diagnosis, treatment, and service models, and achieve a high level of patient satisfaction.

As the first globally approved innovative migraine treatment drug by both the US FDA and the EU EMA, Rimegepant Orally Disintegrating Tablets have been recommended by migraine guidelines in the US, Europe, and China,,, . After receiving approval in China, it is now accelerating its coverage of migraine patients through online and offline integration to meet their diverse medication needs in various scenarios, scientifically "fighting headaches and enjoying life."

About Pfizer: Bringing Life-Changing Breakthrough Innovations to Patients

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Throughout the exploration, development, and production of healthcare products, Pfizer consistently upholds stringent standards of quality, safety, and value. Our global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees in both developed and emerging markets advance human health by driving the prevention, treatment, and cure of diseases to confront the persistent illnesses of our time. Pfizer also collaborates with healthcare providers, governments, and communities to support and expand access to more reliable and affordable healthcare services worldwide. This aligns with Pfizer’s responsibility as a leading global biopharmaceutical company committed to innovation. For over 170 years, Pfizer has been dedicated to making a difference for all who depend on us.

About Meituan Medicine Purchase

Meituan Medicine is the pharmaceuticals and health division under Meituan. Launched as an independent brand in 2020, it aims to become China's go-to platform for purchasing and using medicines under the mission of "keeping everyone healthy." Leveraging Meituan’s nationwide instant delivery network, Meituan Medicine provides users with an average 30-minute delivery service for medicine purchases, fulfilling urgent medication needs and 24-hour nighttime medication requirements. It is also exploring B2C retail services and online pharmacist consultations while collaborating with multiple internet hospitals across China to offer online follow-up diagnosis and prescription services, providing users with convenient and professional medicine purchasing and usage support.